

Official Transcript of Proceedings
NUCLEAR REGULATORY COMMISSION

Title: Advisory Committee on Reactor Safeguards

Docket Number: (n/a)

Location: Rockville, Maryland

Date: Friday, February 6, 2009

Work Order No.: NRC-2649

Pages 1-72

NEAL R. GROSS AND CO., INC.
Court Reporters and Transcribers
1323 Rhode Island Avenue, N.W.
Washington, D.C. 20005
(202) 234-4433

1 UNITED STATES OF AMERICA

2 NUCLEAR REGULATORY COMMISSION

3 + + + + +

4 ADVISORY COMMITTEE ON REACTOR SAFEGUARDS

5 + + + + +

6 559th MEETING

7 + + + + +

8 FRIDAY

9 FEBRUARY 6, 2009

10 + + + + +

11 ROCKVILLE, MD

12 + + + + +

13 The Advisory Committee convened in Room
14 T2B3 in the Headquarters of the Nuclear Regulatory
15 Commission, Two White Flint North, 11545 Rockville
16 Pike, Rockville, Maryland, at 8:30 a.m., Dr Mario
17 Bonaca, Chair, presiding.

18 ADVISORY COMMITTEE MEMBERS PRESENT:

19 MARIO BONACA, Chair

20 SAID ABDEL-KHALIK, Vice Chair

21 J. SAM ARMIJO, Member-at-Large

22 JOHN D. SIEBER

23 SANJOY BANERJEE

24 DENNIS C. BLEY

25 JOHN W. STETKAR

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 ADVISORY COMMITTEE MEMBERS PRESENT: (cont.)

2 DANA A. POWERS

3 WILLIAM J. SHACK

4 MICHAEL T. RYAN

5 OTTO L. MAYNARD

6 CHARLES H. BROWN, JR.

7 HAROLD B. RAY

8 MICHAEL CORRADINI

9 GEORGE E. APOSTOLAKIS

10
11 NRC STAFF PRESENT:

12 KIMYATA MORGAN BUTLER

13 JEAN-CLAUDE DEHMEL

14 TIMOTHY FRYE

15
16 ALSO PRESENT:

17 RALPH ANDERSON

18 J. STEWART BLAND

19
20
21
22
23
24

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

A G E N D A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

OPENING REMARKS BY THE ACRS CHAIRMAN 4

SECY-08-0197, OPTIONS TO REVISE RADIATION
PROTECTION REGULATIONS AND GUIDANCE BASED ON
RECOMMENDATIONS OF THE INTERNATIONAL
COMMISSION ON RADIOLOGICAL PROTECTION 5

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

P R O C E E D I N G S

(8:29:55 a.m.)

CHAIR BONACA: The meeting will now come to order. This is the second day of the 559th Meeting of the Advisory Committee on Reactor Safeguards. During today's meeting, the Committee will consider the following; SECY-08-0197, Options to Revise Radiation Protection Regulations and Guidance Based on Recommendations of the International Commission on Radiological Protection, ICRP, Subcommittee Reports, future ACRS activities, and report of the Planning and Procedures Subcommittee, reconciliation of ACRS Comments and Recommendations, and preparation of ACRS reports.

The meeting is being conducted in accordance with the provisions of the Federal Advisory Committee Act. Mr. Tanny Santos is the Designated Federal Official for the initial portion of the meeting.

We have received no written comments or requests for time to make oral statements from members of the public regarding today's sessions. A transcript of a portion of the meeting is being kept, and it is requested that speakers use the microphones, identify themselves, and speak with sufficient clarity

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 and volume so they can be readily heard.

2 We will now start with the first item on
3 the agenda, which is essentially the SECY-09-0197,
4 Options to Revise Radiation Protection Regulations.
5 And I'll turn now to the Cognizant Member, which is
6 Mike Ryan.

7 MEMBER RYAN: Thank you, Mr. Chairman. I
8 appreciate that.

9 We had a briefing several meetings ago
10 from Dr. Don Cool that gave us the history and
11 background of where we are today, and where 097 was
12 going. And today's presentation by Dr. Kim Morgan
13 Butler will be on the preferred option that the Staff
14 is recommending to go forward with, and Jean-Claude
15 Dehmel is also at the front table to help with some of
16 the background history and questions. So Dr. Cool
17 sent his regrets, but he's on an international trip
18 for the Agency meeting, and I believe it's Vienna this
19 time, so he's hard at work with the rest of the
20 International Community as a similar topic. So
21 without further ado, Dr. Butler, please go ahead.

22 DR. BUTLER: Thank you. Thank you, Dr.
23 Ryan. As you mentioned, my name is Kimyata Morgan
24 Butler, and I work for the Office of Federal and State
25 Materials and Environmental Management Programs.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 Over the last past year or so, I've been
2 working with Dr. Cool, and Jean-Claude Dehmel in the
3 Technical Advisory Group on preparing and drafting the
4 options to revise radiation protection regulations.
5 This eventually became SECY-09-0197.

6 Just to give a little overview, the
7 Technical Advisory Group is comprised of senior level
8 HPs, and senior level scientists throughout the
9 Agency, each representing their representative office,
10 so Jean-Claude represents NRO, and Thomas Young and I,
11 we serve the support function on the FSME side.

12 That Technical Advisory Group reports
13 directly to a Steering Committee, and the Steering
14 Committee is comprised of division-level managers here
15 at NRC, and is Chaired by Mr. Mark Schaeffer. He's
16 the Division of Intergovernmental Liaison and
17 Regulations -- Rulemaking Division Leader, sorry.

18 Dr. Cool really wanted to be here today,
19 but he wasn't able to make it. He's in Vienna, as Dr.
20 Ryan mentioned. He's on a flight back, and he sent
21 his regrets. And I'm just happy that he asked me to
22 join you guys today, and I'm very honored, and thank
23 you for having me.

24 (Off the record comments.)

25 DR. BUTLER: So just to give you a little

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 background, and to let you know why I'm sitting here
2 before you today, the NRC Staff, which was namely Dr.
3 Cool and Mr. Dehmel, they gave an information briefing
4 to the ACRS on November 6, 2008. As part of that
5 presentation, they gave a background on the ICRP, and
6 their recommendations. There was also a robust
7 discussion on the nature of the ICRP, the history of
8 the ICRP, how it came about, who are the members, et
9 cetera. And in the backdrop of that, he also gave a
10 background on the Radiation Protection here at the
11 NRC. And as part of that, he also gave history about
12 our interactions with the International community,
13 with other federal agencies, and with states and state
14 governments, both agreement states, and non-agreement
15 states. Also as part of that discussion, there was --
16 Staff identified technical issues in 10 CFR Part 20,
17 and 10 CFR Part 50.

18 As a result of that discussion that we had
19 within the Technical Advisory Group and the Steering
20 Committee, and the discussions on the Staff identified
21 options, there was a drafting of SECY-08-0197. The
22 last time Dr. Cool came and gave the discussion, that
23 paper was headed into concurrence, and it remained
24 mainly unaltered during that concurrence process. So
25 the paper that he presented before, there's not many

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 changes from what the Staff views are. So that was
2 published, or finalized on December 18, 2008, and is
3 publicly available.

4 So in the next slide, I'm just going to
5 give you some information about that paper, SECY-08-
6 0197. It was a policy issue notation vote paper, and
7 it was provided to the Commission on, as I mentioned,
8 December 18, 2008. It provided the options for the
9 next steps regarding NRC Radiation Protection
10 Standards. And it also provided background on
11 technical issues in 10 CFR Part 20, and 10 CFR Part
12 50.

13 So just to reiterate some of the
14 background. The last time Part 20 was updated was in
15 1991. It was after a 12-year process, and during that
16 process, there were a lot of considerations made. And
17 one consideration was which ICRP recommendations would
18 stand, and which ones would not.

19 As you may know from Don Cool's last
20 discussion, Part 20 is based on ICRP 2630 for the
21 Occupational Dose Limit from 1977. And the public
22 dose limit is based on the ICRP Part 60
23 recommendations, which were finalized in 1990. So the
24 question -

25 MEMBER APOSTOLAKIS: How often does the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 ICRP update its recommendations?

2 DR. BUTLER: Traditionally, they've
3 updated their recommendations every 18 years or so.

4 MEMBER APOSTOLAKIS: Eighteen?

5 DR. BUTLER: Eighteen years or so.

6 MEMBER APOSTOLAKIS: So you're right,
7 around 1991?

8 DR. BUTLER: Yes. And so with that
9 recommendation, I always ask the question myself, why
10 did we choose -- why did we go with the 1977
11 recommendations for occupational, while we went with
12 the new updated, at the time, dose limit for public?

13 Well, at the time, there was a meeting in
14 Paris that ICRP held, and they revealed that they will
15 be changing their occupational limits, and also their
16 public dose limits from 500 millirem to 100 millirem.
17 The NRC, we agreed with the public dose limit
18 lowering, but in order to lower the occupational dose
19 limits, we had to vet it within our system. So,
20 actually, I was very pleased that we already had a
21 full study where we looked at the impacts of the
22 reduced dose limits on NRC licensed activities. And
23 it was a NUREG here. It wasn't finalized until 1995,
24 so we didn't have enough background material in order
25 to reduce the dose limits to the average of 2 rem per

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 year, as ICRP recommends in their 1990
2 recommendations. So Part 20 is based on two sets of
3 recommendations, ICRP 60 and ICRP 2630.

4 And then on top of that, Part 50 was not
5 updated during the last update. That's because it was
6 based on explicit dose criteria. So over the 12 years
7 that they updated Part 20, the only regulations that
8 were also updated with Part 20 were the ones that were
9 cross-referenced to Part 20. So if there were
10 explicit dose criteria, then that wasn't an eligible
11 regulation to update.

12 MEMBER RYAN: Dr. Butler, correct me if
13 I'm wrong, but those Part 50 specific limits are based
14 on 1959 ICRP guidance.

15 DR. BUTLER: Yes.

16 MEMBER CORRADINI: The dose limits - I
17 guess this was probably mentioned in November. I
18 don't remember the answer, so just -- the Part 50
19 limits involved are affecting what part of the
20 operation? I don't remember. Because you said
21 occupational dose, public dose, and then Part 50 is
22 what, for accident calculation?

23 DR. BUTLER: Yes, for specific dose
24 criteria for -

25 MR. DEHMEL: Part 50 is not for accident

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 calculation. They are design objectives in numerical
2 criteria that govern routine effluent releases from
3 nuclear power plant, liquid and gaseous effluents.

4 MEMBER CORRADINI: But I -- it was my
5 understanding, though, that 10 CFR 20 was also partly
6 -- at least the previous tables were, in terms of
7 concentration release, also affected what could be
8 released from effluents. Am I misunderstanding?

9 MR. DEHMEL: No. That's why there are
10 criteria also in Part 20, namely, Appendix B, Table 2
11 addresses effluent concentration limits for all
12 licensees.

13 MEMBER RYAN: Not just reactors.

14 MR. DEHMEL: Not just reactors.

15 MEMBER CORRADINI: And 50 should be
16 consistent with 20.

17 MR. DEHMEL: It's a subset, yes.

18 MEMBER CORRADINI: Oh, it isn't.

19 DR. BUTLER: It is not.

20 MR. DEHMEL: Basically, there are two
21 requirements in the effluent releases, which with
22 respect to reactor operations. One is, a power plant
23 has to, by all means, always comply with Part 20,
24 Appendix B, Table 2 effluent concentration limits no
25 matter what.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 MEMBER CORRADINI: Okay. Everybody.

2 MR. DEHMEL: Everybody. Above and beyond
3 that, there are a lot of design objectives specified
4 in Appendix I that further reduce the amount of
5 radioactivity that's released in the environment. So,
6 for example, the effluent releases from the stack is
7 limited to 5 millirem per year, and liquid effluents
8 limited to 3 millirem per year. And that can be
9 readily converted to corresponding concentrations.

10 MEMBER CORRADINI: But then I'm trying to
11 remember, how does Part 50 control anything given that
12 10 CFR 20 limits are different and lower currently.

13 MR. DEHMEL: Appendix I is not a safety
14 standard. Part 50.34 specifically says that, that
15 it's not a safety standard. Essentially, it's a set
16 of operating requirements that regulate and control
17 some specific operational requirements on the
18 licensees to monitor and control, and minimize liquid
19 effluent and gaseous effluent releases.

20 MEMBER CORRADINI: Okay. Thank you.

21 MR. DEHMEL: So Part 20 is governing in
22 all cases.

23 MEMBER APOSTOLAKIS: Let me understand
24 what Dr. Ryan said. You said that Part 50 was last
25 updated in '59?

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 MEMBER RYAN: The dosimetry calculations
2 methods which ICRP has been responsible for were first
3 promulgated in '59. That's one system of dose
4 calculation that still survives in some parts of
5 supporting regulations today. Some parts use the
6 1970's version, which is 26 and 30, and then the
7 current plan is to synthesize that into a more
8 coherent system, which we heard at our briefing from
9 Dr. Cool, and use publication 103 as the basis.

10 Now, that's going to take some careful and
11 measured work over some period of time, which I think
12 is the essence of the Staff's preferred option to do
13 that systematically and carefully, so that you're not
14 redoing the same thing perhaps two or three times to
15 get it all up-to-date, if there's a more comprehensive
16 plan to make that happen.

17 One thing just as an artifact, nobody in
18 any academic program I'm aware of still teaches ICRP
19 2. In fact, you can't get a copy of ICRP 2, so it's
20 high time to go ahead with the updates.

21 DR. BUTLER: Yes. I only two people with
22 -

23 MR. FRYE: Excuse me a second. This is
24 Tim Frye. I'm the Chief of the Health Physics Branch
25 in the Office of New Reactors. And I just wanted to

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 clarify. I think Jean-Claude and Dr. Butler just
2 mentioned this, but when we talk about Part 50, we're
3 talking now Part 50, Appendix I, which is the ALARA
4 Guidelines, which provide lower, more limiting
5 guidelines for achieving ALARA. And so, it's not --
6 that's the part of Part 50 we're talking about. That
7 is based on ICRP 2, the Appendix I.

8 DR. BUTLER: So Part 50, Appendix I, is
9 based on ICRP 2, which was finalized in 1959. So
10 internally at the NRC, we're on three different --
11 we're regulating based on three different sets of
12 ICRP recommendations, ICRP 2, ICRP 2630, and ICRP 60.

13 So, as you can see, that may cause -- and as you
14 mentioned, Part 20 and Part 50, they're not the same
15 as this point, so that led us to the Staff
16 recommendation that yes, we want to take steps towards
17 moving towards alignment with ICRP 103, as Dr. Ryan
18 mentioned, to have everything on the same accord. So
19 the Staff recommends that the Commission approve
20 Commission approval for Staff to undertake stakeholder
21 dialogue and technical basis development.

22 So in the next slide, I'm going to go into
23 a little detail with the regulatory options, just give
24 you an overview at first, and then give details. So
25 the Staff thought of three options. The first option

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 is a no-action option. With that option, we wouldn't
2 update Part 20, or any of the related regulations. We
3 would simply update the regulatory guides that
4 accompany the regulations. And they're already
5 scheduled to be updated.

6 The second option is to update 10 CFR Part
7 50, and Part 50, Appendix I, those specific -- those
8 criteria. And the third option was to engage
9 stakeholders and develop technical basis to increase
10 alignment of the NRC Radiation Protection framework
11 with ICRP 103.

12 MEMBER CORRADINI: You're going to explain
13 the third bullet more fully?

14 DR. BUTLER: Yes.

15 MEMBER CORRADINI: Okay.

16 DR. BUTLER: Yes.

17 MEMBER APOSTOLAKIS: Or what's the
18 difference between the second -

19 DR. BUTLER: Yes. In the upcoming slides,
20 I'm going to explain each of them. There's a
21 difference there, and I'll get to it in the next
22 slide.

23 So the factors that were considered was
24 the schedule for the technical information. Right
25 now, as I mentioned, ICRP - for example, when I

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 mention ICRP 2630, ICRP 26 was the report, and ICRP 30
2 was the supporting dose conversion factors, et cetera.

3 And so, there's a ICRP Publication 107 planned for
4 103. ICRP publication 107 will not be available until
5 at least 2011 for some of the most used, regularly
6 radionuclides, and 2014 for some of the other
7 transuranic radionuclides. So that would give us a
8 time, the Staff took that into consideration, and we
9 gave thought to what could we do during that time
10 period.

11 Also, we considered new reactor licensing,
12 both current and future new reactor licensing. Jean-
13 Claude mentioned to me before that there may be a
14 second wave of applications, COL, Combined Operating
15 Licensing applications that come in, so we took that
16 into consideration.

17 There's other issues that may be raised
18 outside of the ICRP changes. For example, the waste
19 classification. That waste classification, in and of
20 itself, is not on the table right now, and we may
21 consider that later. And, also, there's the resources
22 that are involved. So last time Part 20 and its
23 related regulations were updated, there were a lot of
24 resources that were involved, so we had to take into
25 account the resource levels for each option.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 So the next slide I'm going through -

2 MEMBER CORRADINI: You're probably not
3 going to go back to your -- you don't have to go back,
4 but the last thing you said about other issues in
5 waste classification, you're not going to talk about
6 that any further?

7 DR. BUTLER: No.

8 MEMBER CORRADINI: So just remind me, by
9 changing this, you would actually alter what's Class
10 B, Class C? It could alter that definition?

11 DR. BUTLER: Well, the last time Part 20
12 was updated, there was no updates to Part 32, Part 50,
13 Part 51, Part 61, or Part 72. So this time we're
14 going to specifically make sure that Part 50 is
15 updated, but some of the other parts, they're not
16 going to be updated this time.

17 MEMBER RYAN: Dr. Butler, on 61, for
18 example, the dose limit is 25 millirem full-body, 75
19 millirem thyroid, and 25 millirem any other organ.
20 That's completely out of step with Part 20 now, so the
21 idea is that that ICRP 2 type of dose standard would
22 be re-evaluated, or maybe even adjusted to be
23 appropriate with perhaps an updated system. That's at
24 least one idea that you talked about, so it wouldn't
25 necessarily affect the concentration tables, but it

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 might affect how you cast a particular dose limit in a
2 different part of the regulation. Does that help?

3 MEMBER CORRADINI: That helps a little.

4 MEMBER RYAN: Okay.

5 MEMBER APOSTOLAKIS: Is the NRC
6 represented on the ICRP?

7 DR. BUTLER: Not specifically. The United
8 States have John Boyce. He's the representative.

9 MEMBER APOSTOLAKIS: He's not affiliated
10 with the Agency?

11 DR. BUTLER: No.

12 MEMBER RYAN: No.

13 DR. POWERS: It's a private entity.

14 MEMBER APOSTOLAKIS: I'm sorry?

15 DR. POWERS: It's not a government entity.

16 DR. BUTLER: Yes, it's not.

17 MEMBER APOSTOLAKIS: Oh, it's a private -

18 DR. POWERS: It's a foundation, or
19 something.

20 MEMBER APOSTOLAKIS: Private foundation.
21 Who's funding them?

22 DR. POWERS: Say that again?

23 MEMBER APOSTOLAKIS: Who is funding them?

24 DR. POWERS: Well, they get grants from
25 government agencies, but becoming a government-

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 controlled organization.

2 MEMBER CORRADINI: Smart move, no bailout
3 money. Huh?

4 DR. POWERS: They have no bailout money.

5 MEMBER CORRADINI: But if I just might.
6 So NCRP is affiliated at all with ICRP. It's a
7 separate national -

8 MEMBER RYAN: That is absolutely correct.

9 MEMBER CORRADINI: -- version of it.

10 (Simultaneous speech.)

11 MEMBER APOSTOLAKIS: So, and there is an
12 understanding that we have to take into account what
13 they say? I mean, how does that work?

14 DR. POWERS: Well, it's the equivalent of
15 Public Law 103.

16 MEMBER APOSTOLAKIS: No, I'm talking about
17 the ICRP.

18 MEMBER RYAN: We're under no obligation to
19 accept anything, but it is -- has to be -

20 MEMBER APOSTOLAKIS: If we don't, we have
21 to explain why not.

22 MEMBER RYAN: That's right.

23 DR. POWERS: Public Law 103, or something
24 like that.

25 MEMBER APOSTOLAKIS: What does the public

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 law say?

2 DR. POWERS: It says if you come up with
3 industrial consensus standards, you've got use them in
4 the regulatory process, unless there's a good, sound
5 reason not to.

6 Now let me ask this question, which may
7 not be appropriate to ask at this point, but I'll ask
8 it anyway, and you can tell me -- it strikes me that
9 when I look at 20 and Appendix I, that as regulations,
10 they are way too detailed, and that's creating a
11 problem for us. When you have updated, quantitative
12 guidance coming down, you have to update the
13 regulations, rather than just updating the reg guides.

14 When we talk about updating, should we be talking
15 about changing Appendix I and Part 20, so that we
16 don't have the quantitative -

17 MEMBER RYAN: If I understand right, Dr.
18 Butler is going to talk a little bit about the exact
19 issue, because it needs attention. We now have three
20 different technical calculations that support dose
21 assessments under the various parts we've heard about.

22 And I think, if I understand their Option 2, and
23 we'll hear about it in just a second, is to move
24 forward to synthesizing that into one coherent system
25 over time, but in a measured way that doesn't upset

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 the apple cart.

2 DR. POWERS: Well, I can understand that,
3 but I note that even in 50.46 we struggle with the
4 quantitative aspects of the regulation, and the
5 detailed calculational aspects of the regulation. And
6 we'd be much happier if all that stuff was in
7 regulatory guides. And here in Part 20, and to some
8 extent in Appendix I, you have an infinite number of
9 quantitative calculations that you're struggling with
10 because the numbers keep changing.

11 MEMBER RYAN: It sure would be nice to
12 have a dose assessment manual that's in one place for
13 all the activities, and maybe that guidance would be a
14 better place for some of the detail. But I think
15 we're still having a need to have a dose limit in the
16 regulation itself, but how you do the calculations,
17 and where some of the tables might be, that's
18 certainly something to think about.

19 MEMBER SHACK: Well, it's just like the
20 PTS Rule, where they're going to insist on putting the
21 embrittlement correlation into the rule.

22 DR. POWERS: Yes, that's madness.

23 CHAIR BONACA: Why is it happening?

24 MEMBER SHACK: Because OGC tells them it
25 has something enforceable, it has to be in the rule,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 which is, presumably, the same reason it's in the rule
2 here.

3 DR. BUTLER: And everything you brought
4 up, we're going to take into consideration as we're
5 developing the technical basis.

6 MEMBER ARMIJO: Everything?

7 DR. BUTLER: Not everything. I mean,
8 well, not everything, specifically, but in terms of
9 structure, in terms of structure and what should
10 remain in Part 20, and what can be sent to a reg
11 guide, et cetera. We're going to take that into
12 consideration, also.

13 MEMBER RYAN: I think it would be helpful
14 if we just think ahead without any specifics in mind,
15 but to have specific briefings on some of those
16 related questions as your process moves along.

17 MEMBER ARMIJO: Going back one slide. In
18 the factors considered, I see a number of things that
19 are sort of administrative.

20 DR. BUTLER: Yes.

21 MEMBER ARMIJO: What are the health
22 benefits of this update? Isn't that going to be
23 considered?

24 DR. BUTLER: We're already operating under
25 adequate health and safety, even with the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 inconsistency of the regulations. So what we're going
2 to consider more is some of the -- the fact that the
3 science will be updated, that there will be more
4 consistency both internationally and within our own
5 regulations.

6 MEMBER ARMIJO: So are the limits going to
7 be reduced, or whatever dose level? Is there -

8 DR. BUTLER: We're going to take -

9 MEMBER ARMIJO: Okay. But you're going to
10 consider that.

11 DR. BUTLER: Right. We'll take it into
12 consideration. So, for example, the embryo/fetus
13 doses right now, 500 millirem a year for NRC. The
14 ICRP 103, it recommends 100 millirem. We're going to
15 take into account what impacts and benefits that would
16 have for our licensees and our stakeholders, if we
17 make that change.

18 MEMBER ARMIJO: So you're not just going
19 to buy into that 100?

20 DR. BUTLER: Not carte blanche, just
21 because ICRP tells us -

22 MEMBER ARMIJO: Good. That's the one
23 change that bothers me the most, because I think that
24 will likely lead to a lot of females not declaring
25 pregnancy.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 MEMBER CORRADINI: And, can actually make
2 it more -

3 MEMBER ARMIJO: Right.

4 DR. BUTLER: Yes, we have to weigh whether
5 -- because we also want to -- right now it's 500
6 millirems, and it goes back from gestation, the whole
7 gestation period; whereas, the ICRP recommendation is
8 100 millirem from the point of declaration forward.
9 So it may be more or less protective, we just have to
10 make sure that we vet that through our process, and
11 decide which one is the best option to move forward
12 with. So that's an example of something that we're
13 going to take into consideration.

14 So the next few slides I'm going to go
15 through and explain why -- how the Technical Advisory
16 Group, and the Steering Committee came up with one
17 option over the other options. So the punch line is
18 Option 3 is the Staff preferred option, and the
19 question is, why is Option 3 the best option, in our
20 opinion.

21 So the first option is a no-action option.
22 If the Commission accepts this option, then they
23 conclude that there's no need for changing any of the
24 current regulations. There's adequate protection, as
25 I mentioned. There is a pro to this, that there is no

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 resources needed. As I mentioned before, the reg
2 guides are -- the Radiation Protection Regulatory
3 Guides, they're on the schedule to be updated, and
4 they're already funded, so no additional resources
5 would be needed. There are a few cons.

6 DR. POWERS: Is there not a pro here that
7 adequate protection is still maintained?

8 DR. BUTLER: I'm sorry?

9 DR. POWERS: Doesn't Option 1 preserve
10 adequate protection?

11 DR. BUTLER: Yes. And I think all of the
12 options -- under all options, there's adequate
13 protection, so that wasn't the main driver.

14 DR. POWERS: Didn't include that, Mike,
15 and I think it should be included.

16 MEMBER RYAN: Well, one thing I think
17 we'll hear about, the last bullet under Option 1, we
18 have a representative from NEI, I believe, who wants
19 to make some comments when we're done, so we'll hear
20 the industry view on Option 1, and what their views
21 are.

22 MEMBER APOSTOLAKIS: Given that the
23 concept of adequate protection is really ill-defined,
24 I don't know how you can say -

25 DR. POWERS: It is not ill-defined.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 MEMBER APOSTOLAKIS: It is.

2 DR. POWERS: It is perfectly well-defined.

3 MEMBER APOSTOLAKIS: No.

4 DR. POWERS: You just don't like the
5 definition.

6 MEMBER APOSTOLAKIS: It is adequate
7 protection when we say it is, so I don't know. I
8 mean, if the international standards have changed, how
9 can you claim -

10 MEMBER ARMIJO: Those aren't international
11 standards. Those are recommendations from an
12 international committee, which doesn't, necessarily,
13 set the standards for the NRC.

14 MEMBER APOSTOLAKIS: I understand that. I
15 misspoke there. But the truth of the matter is -

16 MEMBER ARMIJO: Yes, you did.

17 MEMBER APOSTOLAKIS: -- that I don't know
18 what the pro that says adequate protection is
19 maintained means.

20 MEMBER SHACK: It's only a slide, guys.

21 MEMBER APOSTOLAKIS: The old adequate
22 protection -- the current concept of adequate
23 protection is maintained. That's what -

24 MEMBER SHACK: Fragmentism again.

25 MEMBER APOSTOLAKIS: Right? Dr. Ryan, is

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 that out of line?

2 MEMBER RYAN: I accept your comment.

3 MEMBER APOSTOLAKIS: We have a bunch of
4 regulations and then we say if you meet them, there is
5 adequate protection.

6 MEMBER RYAN: I think as a practical
7 matter, too, other than the principle of adequate
8 protection, which I think the regulations do
9 accomplish that goal, but when you have three separate
10 systems that are the technical underpinnings of
11 various components of the requirements, it becomes
12 very complicated to try and translate I'm meeting it
13 over here, I'm meeting it over there, but I have to
14 change my calculational methods to demonstrate that.
15 So the inconsistencies from one part of the
16 regulations to the other really make it difficult to
17 demonstrate that you are adequately protecting across
18 the scheme.

19 MEMBER ARMIJO: Yes, but that would be a
20 good thing to correct with or without any new ICRP
21 recommendations, wouldn't it?

22 MEMBER RYAN: Yes. And I think the idea
23 here is that that's a principal thrust of why it
24 wasn't done last time, and the consistencies issues
25 are what are driving it this time, if I understand the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 Staff correctly.

2 DR. BUTLER: Exactly. And that's why it's
3 listed under a con.

4 MEMBER APOSTOLAKIS: Isn't it true that
5 when you -- let's say we decide to change the
6 standards. We are, essentially, redefining adequate
7 protection?

8 MEMBER RYAN: No.

9 MEMBER APOSTOLAKIS: Why not? If you met
10 this here, you know, plus other things -

11 MEMBER SIEBER: The same boundary.

12 MEMBER RYAN: Let's just say the dose
13 limit is the same for a given circumstance, and we're
14 updating the clarity with which you can demonstrate
15 it, but I don't know that we're really -

16 MEMBER APOSTOLAKIS: That doesn't affect
17 that.

18 MEMBER RYAN: All right. Why don't we let
19 Dr. Butler continue.

20 DR. BUTLER: So the cons are that it's not
21 responsive to the current scientific information.
22 Some of the information, as we mentioned, is based on
23 1959 science, and we want to bring that up-to-date.
24 The regulations would remain inconsistent. We would
25 have these three different recommendations driving our

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 recommendations, our regulations. It does not improve
2 internal consistency. So, for example, if you have a
3 worker who wants to work in the United States,
4 currently in Canada, and some of the European nations,
5 the dose limit, the annual worker dose limit, is 2 rem
6 average per year. That's 10 rems over five-years, or
7 no more than 5 rems in one year. So if they come to
8 the United States and they work just for one year,
9 that could impact them if they wanted to return to
10 their home country. So that's a international
11 consistency issue, a trans-boundary issue that we have
12 with workers here.

13 Also, the Nuclear Power industry has
14 stated preference to update some of the requirements.

15 Dr. Cool often mentions in his talks that some of the
16 new employees are not trained on the older technology,
17 the older methodology. And then when they go into
18 industry, they have to relearn some of the old science
19 that our recommendations are based on. And I also
20 heard -

21 (Off the record comment.)

22 DR. BUTLER: And I heard this somewhere in
23 the audience today, also, that there's this
24 inconsistency, so there's a preference to update based
25 on that.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 MEMBER APOSTOLAKIS: It seems to me the
2 right word there is Commission decides, not concludes.

3
4 DR. BUTLER: Yes.

5 MEMBER APOSTOLAKIS: If you want to
6 conclude, you have to have some resources to
7 investigate and decide, and make -- reach a
8 conclusion. Right? That's nitpicking, though, but
9 that's why we're here.

10 DR. BUTLER: Okay. So the second option
11 is to update Part 50, Appendix I. And the Commission
12 would conclude or decide that there is no basis to
13 update Part 20, but agrees to update Part 50, and Part
14 50 Appendix I to the current Part 20 methodology. So
15 at least we can -- the Staff wanted to acknowledge
16 that we wanted to get rid of some of the inconsistency
17 between Part 50 and Part 20 as an option. It needed
18 to be an option on the table.

19 There's a pro to that. There's a reduced
20 burden for the nuclear power by improving the
21 consistency between Part 20 and Part 50. And there's
22 a few cons. One is that it's not responsive to the
23 current scientific information, the same as Option 1,
24 and the same as with Option 1, it does not improve the
25 internal consistency. And it's only partially

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 responsive to the industry interests, so I'm sure that
2 the most up-to-date science and consistency would be
3 the most optimal choice.

4 So with that as the backdrop, the Staff
5 decided that we would like to recommend Option 3, and
6 that is yes, let's consider updating Part 20 and Part
7 50. And, in that process, before we run out and start
8 rule making, let's engage stakeholders and develop a
9 technical basis. So for every rule making, a
10 technical basis is required. And within that
11 technical basis, we would draft some supporting
12 documents, regulatory analysis, or environmental
13 impact, a cost/benefit analysis, a backfit analysis,
14 so let's go out and engage the stakeholders first so
15 that we'll have information to make these decisions.

16 MEMBER CORRADINI: May I just ask a
17 question? So, is the process you will use for Option
18 3 similar to the process you did 12 years ago?

19 DR. BUTLER: No, it's not the same. I
20 don't think that there was this first initial buffer
21 time of engaging the stakeholders before going into -

22 MEMBER CORRADINI: In the prior -

23 DR. BUTLER: Yes.

24 MEMBER CORRADINI: Okay. If you're
25 getting into this later, that's fine. I'm trying to

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 understand process relative to timing.

2 DR. BUTLER: Right.

3 MEMBER CORRADINI: That is, given new
4 plants, given all of this, is the 12 years an
5 acceptable process time?

6 DR. BUTLER: Well, I'm not sure if it's
7 going to take 12 years this time. I can give you what
8 we have in mind right now.

9 MEMBER CORRADINI: Okay. That's fine.

10 DR. BUTLER: Right now we have in mind a
11 two-phase process over the next -- for this option,
12 engaging the stakeholders, in FY 09 we want to go and
13 just educate some of the stakeholders, and licensees,
14 and the public on what was included in ICRP 103, and
15 let them know that it's out there, and that there are
16 some alternatives, newer methods that are out there.
17 And then FY 10, we would propose to go out and solicit
18 some of the impact considerations, benefits that the
19 licensees or the public may see with adopting these
20 regulations.

21 MEMBER CORRADINI: Thank you very much.

22 DR. BUTLER: Okay. So there are some pros
23 to this. It starts the process that could improve the
24 scientific basis, improve the internal regulatory
25 consistency, and increase the international

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 consistency, all the topics we hit on before, talked
2 about a little before. And this process would
3 actually give us a unique opportunity to engage the
4 stakeholders early in the process. And that would
5 give us a chance to identify the issues and the
6 solution before the beginning of rule making.

7 So after we finish this technical basis
8 development, engagement of stakeholder process, we
9 would then -- and we, as the Staff, we would -- the
10 Staff would actually write another SECY paper with
11 options for rule making, and present that to the
12 Commission. So we're not proposing rule making right
13 now, we're only proposing that we develop enough
14 material to draft the technical basis, and to
15 understand, get a higher understanding of the issues.

16 There is a con. There is the resources
17 necessary for stakeholder engagement in technical
18 basis development, so there will be some resources
19 that are needed, both at a Staff level, and a timing
20 issue. And we would have to go in the public, so
21 there will be some contract dollars also associated
22 with it.

23 DR. POWERS: What resources does the
24 Agency expend in training new people, especially in
25 the health physics area, to understand an inconsistent

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 and incoherent set of regulations?

2 DR. BUTLER: Okay. Well, there is an
3 overview of health physics training. There's an
4 introduction, and a more advanced health physics
5 training, but in terms of the -

6 DR. POWERS: What I'm asking you is, that
7 you've made a point here of resources being necessary
8 to carry out this option, successful completion of
9 this option seems to me that it accrues some benefit
10 with regard to resources, especially as we hire young,
11 bright-eyed and bushy-tailed people coming in trained
12 in one set of regulations, to come in and learn four
13 sets.

14 DR. BUTLER: Right. I agree.

15 DR. POWERS: And I have no idea what the
16 magnitude is there, but it's got to be none, zero.

17 MEMBER RYAN: I think there's another
18 added part to that, Dr. Powers, and that's the
19 regulated community.

20 DR. POWERS: They have the same problem.

21 MEMBER RYAN: They have the exact same
22 problem. And their health physicists aren't as well
23 trained on the -

24 DR. POWERS: Should we ask them to pay for
25 these resources. Well, I guess -

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 (Simultaneous speech.)

2 MEMBER RYAN: And without correction, it
3 will only become a problem that's more exacerbated
4 over time.

5 DR. POWERS: I would think it would not
6 only be a problem with the people you do hire, I think
7 it would positively detour many young hires saying
8 here we're going to bring you into a system that's
9 archaic, it's strange, it's inconsistent, and you can
10 flounder around in this area, or you can go work for a
11 modern organization, like the U.S. Army, and do it
12 right.

13 DR. BUTLER: Or even globally, this is a
14 global economy now -

15 DR. POWERS: Yes. Absolutely.

16 MR. FRYE: I think another resource
17 benefit that would be considered would be that it's
18 not only training of staff, but it's also the -- these
19 improvements will make our licensing reviews much more
20 effective and efficient.

21 DR. POWERS: Confusion costs are non-zero,
22 as well.

23 MR. FRYE: So that would be a resource
24 savings, in addition to the staff training.

25 DR. BUTLER: Okay.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 DR. POWERS: I'm just trying to help you
2 with your talk.

3 DR. BUTLER: So, just to reiterate the
4 Staff recommendation, the Staff recommends Option 3 to
5 begin the process of moving towards a greater degree
6 of alignment with ICRP Publication 103. We propose to
7 begin stakeholder dialogue with stakeholder
8 communities on the technical issues and options. So
9 just to give you an overview, we're still waiting for
10 the Commission votes. We don't have any votes either
11 way, and we don't know which way it's going to go
12 right now, but we've been planning ahead just in case.

13 So, as you know, if you want to make a presentation
14 at a professional society meeting, you usually have to
15 put that marker on the calendar early. So right now
16 we have markers on the calendar for the Conference of
17 Radiation Control Program Director, CRCPD, for the
18 Society of Nuclear Medicine, and for the Health
19 Physics Society.

20 We've also been in discussions with NEI.
21 NEI met with the NRC senior management a few weeks
22 ago, and they were supportive of the Staff proposals.

23 And these options were presented at the NSIAC. They
24 were supportive of the Staff proposals, and they had a
25 great willingness to work with us to engage on the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 issues in the nuclear power industry.

2 So also during this process, we're going
3 to begin technical basis development and interact with
4 other federal and state agencies to foster consistency
5 in direction and approach. So, for example, I've
6 heard this question often, even within the internal
7 staff meetings, how are we going to align with other
8 federal agencies, and with states, both agreement and
9 non-agreement states? So we're definitely going to
10 make sure, make that a priority.

11 Don is a part of the inter-agency Steering
12 Committee on Radiation Standards, and he's going to
13 keep -- Dr. Cool is going to keep focus. He's going
14 to keep us on the pulse of that, and also with state
15 agencies, because there's definitely going to be a
16 compatibility issue if we update Part 20 and Part 50.

17 MEMBER CORRADINI: So that's, I guess -- I
18 want to understand and clarify. So you said a couple
19 of things there that I don't appreciate. Is there
20 going to be -- let's say the Commission decides on
21 Option 3. Then you proceed with Phase I. Then you
22 proceed with rule making to make some sort of
23 consistent set, whatever the limits are, a consistent
24 set.

25 DR. BUTLER: No, no, no. We're going to

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 do Phase I. Phase I is just going out and educating.

2 MEMBER CORRADINI: Right.

3 DR. BUTLER: Phase II is going and getting
4 a list of problems, impacts, and benefits.

5 MEMBER CORRADINI: Right.

6 DR. BUTLER: And then if I could give you
7 a Phase III, Phase III is to draft a rule making
8 options paper and present that to the Commission.

9 MEMBER CORRADINI: Okay. And so let's say
10 we made it all through -

11 DR. BUTLER: And then they would decide -

12 MEMBER CORRADINI: Okay. And let's say we
13 made it all through that and they decide, you said a
14 couple of things that I don't appreciate; which is,
15 what is the impact -- what is the difference in impact
16 between agreement and non-agreement states and state
17 agencies? Because what I just heard is, even though
18 you might make yourself consistent, inconsistencies
19 can exist down the line, and I don't appreciate that.

20 DR. BUTLER: Well, some of the other
21 agencies are in the same boat that the NRC is.
22 Internally, they're inconsistent with their
23 regulations. And I was just saying that we were going
24 to work together with them, maybe not on the state
25 side. The state, they have a compatibility issue

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 there. They have to be -- their regulations have to
2 be compatible with the NRC regulations.

3 MEMBER CORRADINI: Okay.

4 DR. BUTLER: And so I said there may be a
5 compatibility issue there that we would have to
6 consider in this technical basis.

7 MEMBER CORRADINI: Okay.

8 MEMBER RYAN: It will have an impact on
9 states if they have to make changes, which they will
10 likely have to do. But recall that agreement states
11 are required by being an agreement state, and correct
12 me if I'm wrong, but all the radiation protection
13 limits and standards are in a compatibility category
14 where they must change them.

15 DR. BUTLER: Right.

16 MEMBER CORRADINI: And the non-agreement
17 states?

18 MEMBER RYAN: And the non-agreement states
19 are regulated by NRC, if they've got material
20 licenses, so they have to follow the federal
21 regulations.

22 MEMBER CORRADINI: It's more of a matter
23 of how it works its way out.

24 MEMBER RYAN: Yes. And I think it's a
25 matter of the same question that Dr. Powers raised,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 which is timing, and resources, and all that for how
2 long do they get to become compatible? And that's
3 kind of what the process was the last time that
4 changes were made.

5 DR. BUTLER: Yes. And for Part 20, the
6 last time Part 20 was updated, they were given a
7 three-year period to become compatible with the
8 regulations.

9 MEMBER CORRADINI: Thank you.

10 DR. POWERS: If I was in a profit-making
11 business here, would I not look upon radiation
12 protection as a core competency of the agency? I
13 mean, I'm just thinking of a Washington Post headline
14 that says NRC uses outdated regulation, radiation
15 standards. I mean, it doesn't sound like something
16 that I would like to see if I were a Commissioner.

17 MEMBER RYAN: I'll give you my own
18 personal view of that. I guess, my view is that while
19 there are some technical differences among the three
20 systems that could be improved by making them more
21 consistent, I think Dr. Butler rightly said that our
22 regulations are protective of the worker, and public
23 health and safety.

24 DR. POWERS: You have adequate protection.

25 MEMBER RYAN: You have adequate

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 protection, so I think that's the measure by which I
2 would judge the system now. Now, could it be made -

3 DR. POWERS: What I'm asking is that the
4 measure of that the public gauges the agency by?

5 MEMBER ARMIJO: Well, who knows?

6 MEMBER RYAN: Who knows?

7 DR. BUTLER: It just all depends on
8 whether it's going to be more conservative, or less
9 conservative, and we don't know that yet.

10 MEMBER RYAN: And I think the Staff is
11 timely in this assessment, and in their offering to
12 the Commission, because 103 is just barely has the ink
13 dry on it. I mean -

14 DR. POWERS: Very barely.

15 MEMBER RYAN: -- the agency and Dr. Cool's
16 leadership on the Committee has been actively engaged,
17 as you know from the past letters that the ACNW and
18 ACNW&M wrote on criticizing and offering constructive
19 criticism how to improve 103. I mean, we finally get
20 to the -

21 DR. POWERS: There's room.

22 MEMBER RYAN: There is, so I think that's
23 - it's not something that's been sort of on the table
24 for years and they're just now thinking about it.
25 It's something where they're reacting to very current

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 recommendations of the international body.

2 VICE CHAIR ABDEL-KHALIK: Now, many
3 licensees have administrative limits which are well
4 below Part 20 limits for radiation worker exposure.
5 And going to 103 may have essentially minimal impact
6 on the licensees. Wouldn't it help you in this
7 process to start collecting data, or generating a
8 database on these administrative limits that are
9 imposed by the licensees at this time?

10 DR. BUTLER: Exactly. That would be one
11 of the first things that we would do in terms of
12 developing a technical basis. Right now, this NUREG
13 that I held up before, CR 6112, it's a 1995 document,
14 but it's -- the impact would reduce those limits on
15 NRC licensed activities. So we would update that
16 through contract dollars through a National Lab, and
17 we would also go out and start engaging the
18 stakeholders. We would update information that will
19 help us develop the technical basis.

20 MEMBER MAYNARD: I doubt that it's going
21 to be much of an impact, because like Said said, most
22 of the administrative limits are down there, but what
23 it does do is put you closer to the regulatory limits.

24 And it may be an increased workload on inspection and
25 other activities, because a big difference in minor

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 exceedence of an administrative limit versus minor
2 exceedence of regulatory limits, so that could be an
3 impact there to the regulator, too.

4 MEMBER SIEBER: I think the impact is
5 going to be to have licensees lower their
6 administrative limits. The reason why those limits
7 are set the way they are is to provide some protection
8 against violation of the law and some kind of early
9 warning. And that's the way the licensee assures
10 compliance. If you take that margin out between the
11 regulation and the administrative limit out of there,
12 then that buffer disappears, and licensees are
13 unlikely to do that. So I think that the net effect
14 of changing the regulation is to change the
15 administrative limit also.

16 MEMBER RYAN: And I think, too, that the
17 nuclear power industry, and again we'll hear from a
18 representative shortly, will talk a little bit about
19 that. But the medical community, particularly
20 investigative radiology, where nuclear medicine or CT
21 scans or other kinds of devices, where the doctor's
22 hands are actually involved with the patient during
23 some exams and so forth, those areas where there's
24 more likelihood of challenging limits than perhaps in
25 some of the other regulated industries. So the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 medical community would be probably, in my view, an
2 area where you'd hear some feedback on that.

3 DR. BUTLER: And that was the conclusion
4 of the 1995 report.

5 MEMBER SIEBER: Exactly.

6 DR. BUTLER: That 5 rem across the board,
7 it was doable, 2 rem, some licensees would be
8 impacted, mostly industrial radiographers and some of
9 the medical community, and 1 rem, it wasn't -- it
10 looked at 5, 2, and 1, and at 1 rem it was actually
11 not an option, because too many people would be
12 impacted.

13 MEMBER SIEBER: In the case of the medical
14 community, though, care givers are not covered, or
15 patients are not covered by the regulations, but care
16 givers are. Certain care givers are not, but
17 professional care givers are, employees of hospitals
18 or what have you. Greater impact comes in the
19 radiographer category, well logging, things of that
20 nature, where the dose is fixed by the technical
21 requirements of the job being done, and there is some
22 ancillary dose to workers that occurs to those
23 performing the work. It's going to be modification of
24 equipment, change of administrative limits, and so
25 forth.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 DR. BUTLER: And the good thing about the
2 proposal in developing the technical basis is that
3 we're going to take these things into consideration,
4 because Dr. Cool went over some technical issues last
5 time, such as the dose limits, and also constraints,
6 and also he mentioned a little bit about collective
7 dose, and also Jean-Claude mentioned some criteria
8 that would be updated or considered during the updates
9 to Part 50 and Part 20. So we would take all these
10 things into consideration.

11 MEMBER RYAN: Thank you. I guess is Mr.
12 Anderson here?

13 (Off the record comments.)

14 MEMBER RYAN: Tell us who you are, and all
15 that.

16 MR. ANDERSON: My name is Ralph Anderson.
17 I'm with the Nuclear Energy Institute. I'm the
18 Director of Radiation Safety in Low-Level Waste, also
19 a certified Health Physicist.

20 What I'd like to do is just make three
21 points directly germane to the SECY paper and the
22 Staff recommendations. But given the discussion that
23 ensued, which I found very productive, and
24 interesting, I'd like to also offer some additional
25 comments.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 First of all, as captured in the
2 presentation, and in the SECY paper, we've been very
3 forthcoming that we recognize and welcome an eventual
4 alignment of NRC regulations with the International
5 community. We're already in a global nuclear
6 industry. We are already using workers from other
7 countries, and those other countries and their
8 employers, especially, are already starting to express
9 a desire that we not allow workers to get exposures
10 within our regulatory context that would greatly limit
11 their ability to continue to work outside of the
12 United States, so it's an issue we're confronting
13 today.

14 The data that NRC collects annually and
15 publishes is very informative, and I commend it to the
16 ACRS to take a look at it. But the exposure data for
17 workers not only at nuclear power plants, but in
18 several other industries that are required to report
19 data shows you quickly who might be impacted, for
20 instance, by lower dose limits. So it's not an
21 unknown, it's actually very well quantified.

22 In the nuclear industry, 82 workers in
23 2006 received doses greater than 2 rem a year, not
24 from a single facility, but in the large, they are
25 workers that work at several facilities during the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 course of the year. In general, they are highly
2 skilled irreplaceable workers, highly certified
3 welders would be a good example, so if one
4 contemplated that they would be less available to do
5 work as a function of reduced dose limits, it's not
6 that you just call down the street and say well, send
7 me somebody else. There isn't somebody else, so we
8 see it as a transition issue, and we embrace that as a
9 transition issue. And we don't look at that as an
10 obstacle in making an eventual change, we look at it
11 as a challenge to figure out how to make it right.

12 More importantly, and to pick up your
13 point on the administrative dose guidelines that we
14 use, which really is key from our perspective, that
15 is, in fact, the way that we control doses at the
16 plants, as our administrative criteria. It's been
17 many, many years since we've actually challenged
18 regulatory limits. If you consider, for instance, the
19 possibility of a 2 rem a year limit, which is the
20 simplified approach that many regulatory agencies have
21 taken overseas, rather than trying to average doses
22 over a 5-year period, what I did about a year ago is I
23 just polled all my colleagues, namely radiation
24 protection managers at nuclear power plants and I said
25 if you had a 2 rem a year regulatory limit, what would

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 be your tolerance for letting someone go into the
2 plant with the possibility of a regulatory over-
3 exposure? Where would you set your administrative
4 dose guideline? The highest number I got from anybody
5 was 1.5 rem, most were a little more comfortable
6 around 1.2 rem. So when you apply that number to the
7 data, now you're talking about 1,000 to 1,500 workers,
8 likewise, generally workers that are highly skilled
9 and experienced. The reasons they're in the areas of
10 the plant where dose occurs is because they are
11 particularly qualified and competent to do the work in
12 those areas. So, again, it has implications on
13 workforce in the long run. And, of course, this is at
14 the same time, as you know, that we're confronting
15 workforce issues associated with aging workforce and
16 so forth, so it's a big challenge. But we welcome
17 that challenge, and we really, as our key number one
18 point, we welcome support, and strongly encourage
19 going forward with an alignment to accommodate the
20 fact that we're in a global workforce.

21 We, in fact, are doing a study this year
22 under the auspices of our NSIAC, which we all learn
23 how to pronounce acronyms after we create them, but
24 that's the NSIAC she referred to. As most of you are
25 aware, that actually is the collective of all of the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 chief nuclear officers from all of the utilities
2 operating nuclear power plants, so it's not NEI, per
3 se. It really is the industry directly. In fact, Mr.
4 Ray was a member of that august organization at one
5 time.

6 We had this discussion actually two weeks
7 ago, and conveyed to the Executive Director of
8 Operations our endorsement for going ahead with Option
9 3. We conveyed that more directly in a formal comment
10 letter that we submitted a few days ago on some
11 proposed draft regulatory guides on radiological
12 effluents. We called out the SECY paper, and
13 reiterated our support of Option 3 in that SECY paper,
14 so formally we're there.

15 A second point that I wanted to make is
16 that we think that the idea of going out and getting
17 the necessary input from stakeholders, and especially
18 coupled with educating many of the stakeholders that
19 don't understand the nature of these proposed changes
20 is vital. As mentioned, that was not done with the
21 previous revision. Many of us who were around and
22 actively participated in that previous revision, and
23 certainly one significant lesson learned is that
24 beyond the fuel cycle facilities and the nuclear power
25 plants, and to a lesser degree perhaps radiographers,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 and a few other communities, both the states and the
2 vast majority of materials licensees were really
3 oblivious to the revisions to Part 20, such that when
4 the final rule was issued, there were actually some
5 states that were not aware of that. They didn't know
6 there was a new Part 20, and there were hundreds,
7 virtually thousands of licensees that had no idea that
8 the basic regulations had been changed, and that they
9 would need to change their programs. So the NRC had
10 to twice extend the implementation period. It
11 ultimately ended up being three years, or perhaps even
12 four, I'm not sure now, to accommodate the fact that
13 inspectors would show up and say well, show me what
14 you're doing to change to meet the new regulation, and
15 the licensee would say what new regulation is that?

16 Now, what I would like to offer to the
17 ACRS, and we'll make a similar recommendation, I have
18 not found anywhere a really good lessons learned from
19 this previous massive rule making that was undertaken.

20 And one thing that I think would be very important to
21 build into the several year process that NRC has
22 envisioned to make better preparations for rule
23 making, there still are some people alive in the
24 agency, there are probably others available, and there
25 certainly are stakeholders, like myself, still around,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 and which I think it would be very useful to poll
2 people's ideas on lessons learned from the previous
3 rule making, and bring those up, make them transparent
4 to everybody, and not make the some mistakes of the
5 past, because this idea is only one.

6 Another one I will give you as an example
7 is at the time that the rule was finalized for
8 implementation, virtually all of the regulatory guides
9 either were still published in draft for comment, or
10 had not even been published yet, so we were trying to
11 implement a regulation without the benefit of
12 regulatory guidance up front. So there's many lessons
13 to be learned, and I commend everyone to figure out a
14 way to capture those, and formally place those into
15 the planning process.

16 Finally, and there has been reference to
17 this, and I really appreciated some of the comments of
18 the members of the Committee in this regard,
19 especially Dr. Powers. I'd like to say that fine
20 minds think alike, but it would be a shame, I think,
21 if we went through this entire process without overall
22 improving the efficiency by restructuring the rules
23 themselves in their entirety.

24 The fact is that we do have a number of
25 regulations that have their own independent dose

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 criteria, which is why we're so disjointed right now.

2 There's no reason why one regulation can't contain
3 all of the dose criteria, why one reg guide can't
4 contain all of the methodology for how you calculate a
5 dose. I mean, that would be fundamental, I think, in
6 any good business, so I commend that the Agency take a
7 much broader approach than just simply updating
8 numbers in regulations for the sake of consistency.
9 There's a lot of reform opportunity. And I agree
10 also, specifically, that there's a lot of detail in
11 regulation that should probably be moved into
12 regulatory guidance.

13 A couple of comments I wanted to make in
14 response to some of the observations of the members.
15 It's a good question for Office of General Counsel,
16 but there has been over many, many years a discussion
17 of whether, in fact, a dose limit constitutes a legal
18 definition of adequate protection of health and safety
19 as called for in the Atomic Energy Act, so that's an
20 interesting issue to take a look at. My understanding
21 over the many, many years since the AEC was that that
22 was a given reason why an actual dose limit would need
23 to be in a regulation, rather than in a reg guide.
24 But that's a good question to pose to legal folks,
25 because really it's a legal question.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 Secondly, the headline news on the
2 outdated NRC regulations, that was in the Washington
3 Post in I want to say 1997-1998, when the interesting
4 interactions were going on between the Environmental
5 Protection Agency and the Nuclear Regulatory
6 Commission over the Commission's new license
7 termination rules. There were a whole series of
8 articles in that regard, so the headline already
9 occurred. And, in fact, what it prompted was a very
10 divisive set of interactions between two federal
11 agencies with local stakeholders at a number of plants
12 decommissioning in New England. They were speaking
13 different languages, and talking about different
14 numbers, and managed to convince most of the public
15 that I talked to that neither agency knew what the
16 heck they were talking about, so that was the outcome.

17 Both agencies are equally incompetent. So that, in
18 fact, has occurred. And yes, I could see that coming
19 up in a different vein today.

20 I also point out that this has been the
21 subject of at least two GAO reports, one sponsored in
22 the late 1980s by Senator John Glenn, which concluded
23 that we ought to get our act together and create
24 consistent regulations. And more recently, about five
25 years ago, a GAO report commissioned by Senator Pete

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 Domenici, which reached the same conclusions, except
2 just pointed out that the situation has just continued
3 to get much worse; because whereas we used to be two
4 generations out of date, now we're three. So there's
5 a rich background of thoughtful people who have looked
6 at this issue, concluded that we should fix it, and
7 here we are, and so I suggest that this is our
8 opportunity to do so.

9 I had mentioned the problems that arose in
10 decommissioning, but for some of the members on the
11 Committee, and certainly for some of the NRC Staff,
12 they'll recall that we've confronted this issue of
13 differences in a way that has been less than good in
14 its outcome with the groundwater contamination that
15 has shown up at nuclear power plants, where we've had
16 to try to rationalize the NRC limits for public dose,
17 and how those relate to concentrations in liquid
18 effluents versus the Safe Drinking Water Act criteria,
19 which actually come from quite a different basis. And
20 having those types of discussions, again, what I saw
21 convinced local stakeholders where those discussions
22 occurred that we really didn't know what we were
23 doing, or what we were talking about.

24 Now, for one who looks closely, I fully
25 agree that throughout all of this confusion, we've

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 managed to protect health and safety. And it's not in
2 spite of, it is actually because of the way that we
3 have formulated our regulations, and that is for every
4 limit there's also a requirement to maintain exposures
5 as low as reasonably achievable. And, truthfully,
6 that's what we all work to, we don't work to limits.
7 If we can do something that's reasonable and cost-
8 effective to further reduce dose, we do. That's the
9 reason why the average nuclear power plant worker's
10 exposure per year is 140 millirem, which is a minute
11 fraction of 5,000 millirem a year. And that's why the
12 average member of the most exposed member of the
13 public around a nuclear power plant has doses that are
14 a fraction of a millirem, nowhere near the ALARA
15 criteria that are spelled out in Appendix I, and
16 certainly light years away from the actual limits that
17 are specified in Part 20.

18 It's the outlier situations, though, and
19 one was illustrated graphically in medical. In
20 general, this probably won't have a large impact on
21 the medical community, but there are specific
22 situations where it could have a very significant
23 impact. And I think, as with the highly qualified
24 specialized workers at nuclear plants, these are some
25 of the things that we need to bring out in this

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 information-gathering that NRC goes forward to. So I
2 would simply encourage the Staff throughout that
3 process to maintain an open mind, rather than go in
4 with a strawman and basically say, tell me what's
5 wrong with it. I just throw the door open, and get as
6 broad and free-thinking input as you can get.

7 Appreciate the opportunity to make some
8 comments, certainly happy to respond to anything
9 before I sit down.

10 MEMBER BANERJEE: Could you tell me the
11 difference in the groundwater of concentrations that
12 the Safe Drinking Water Act and the NRC have?

13 MR. ANDERSON: Yes. Fortunately, they
14 both use 1959 technology, so they're both
15 scientifically irrelevant. And that's a fact. I mean,
16 you could make a judgment about that, but that is a
17 fact. They don't have anything to do with
18 contemporary science. They're fantastically low
19 numbers in both cases, so again, we end up protecting
20 health and safety even when you compare them to
21 contemporary scientifically-based criteria. But in
22 essence, EPA uses different assumptions about the
23 nature of exposure from drinking water to calculate
24 what the resultant dose might be than the NRC does.
25 So there, even though they start with a common vintage

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 of ICRP, so at least they're using the same units and
2 terminology, calculations that they make in terms of
3 how long a person is drinking that water, and how much
4 water they drink a day and so forth, is different
5 enough that when the EPA says well, this amount of
6 radioactivity will give you 4 millirem a year, in NRC
7 space it would give you much less than that for many
8 radionuclides.

9 Conversely, there are some other
10 radionuclides where it's exactly the reverse, and
11 that's where it gets convoluted. Strontium-90, for
12 instance, as an example, EPA's methodology tells you
13 it's 4 millirem, NRC's methodology tells you it's, if
14 my memory serves me right, about 68 millirem for the
15 same amount of Strontium-90.

16 MEMBER BANERJEE: Same concentration.

17 MR. ANDERSON: Yes.

18 MEMBER RYAN: Some of the intake
19 assumptions are very different. For example, you
20 think about 2 liters of water a day as a standard
21 intake. Nobody drinks 2 liters of water from their
22 tap a day, so that's a conservative assumption. There
23 are some other differences from one to the other. It
24 is a Rosetta Stone that has to be sorted out to figure
25 out why it's different.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 MEMBER BANERJEE: It's not going to get
2 sorted out here.

3 MR. ANDERSON: It's not.

4 The third bullet on that slide is --
5 within all of this is probably the greatest hurdle of
6 all. And that's where the two GAO reports went, is
7 that when all the dust settles, and if NRC goes
8 forward and achieves this, I think it's doable. We
9 still may end up with all of these residual issues
10 associated with other agencies doing things.

11 Now, lest you think it's completely
12 unimportant, and I know you wouldn't say that in a
13 callous way, but if at the end of the day you decided
14 it wasn't particular risk-significant, it should be an
15 issue of concern as it relates to the topic of off-
16 site protective action guidelines developed by the EPA
17 vis a vis recommendations and analytical things that
18 would be undertaken within a plant in the case of a
19 real accident, and equally important with subjects
20 like improvised nuclear devices that are radiological
21 dispersion devices. This crossover in methodologies
22 does play a role in that, not challenging public
23 health and safety, but thoroughly confusing decision
24 makers that, at best, have a very rudimentary
25 understanding.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 A good example that we played out some
2 years back was that the alert criteria in virtually
3 all emergency plans and tech specs are based on the
4 Appendix I ICRP 2 methodology. The assessment of
5 dose, at the alert, one of the things you do is you
6 start off site dose assessment and projection. When
7 you step into that, you step into ICRP 26 methodology.

8 And when you run the calculations with the ICRP 26
9 methodology with the nuclides that we would deal with
10 in an accident, the first thing you find out is that
11 you're not at the alert level. So there's an example
12 of transition.

13 You call the local community and saying
14 we're declaring an alert. We've got 15 minutes to
15 start talking to you, and getting things stood up, and
16 we'll start sending you our dose projections, and you
17 call them back 15 minutes later and say okay, we've
18 recalculated. No, we're not in an alert. You can go
19 back to sleep now. We're going to go take care of
20 business. So, hypothetically, it sets up -

21 MEMBER SIEBER: But you have to call them
22 back after that.

23 MR. ANDERSON: Beg your pardon?

24 MEMBER SIEBER: You have to call them back
25 after that, though.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 MR. ANDERSON: Yes. That's right. You
2 could find yourself in a -- but I'm just trying to
3 point out that the reasons go far beyond just a desire
4 to have all things more or less look alike, and to
5 train people easier and things like that. There are
6 real issues that can exist as a result of analysis, or
7 as a result of the real world, if certain conditions
8 ever happen to pop up. And the groundwater, in my
9 mind, is a good example.

10 We've known for years the disparity and
11 differences. It's just that suddenly when we were
12 called upon to have to explain those to decision
13 makers, I will tell you two people that we personally
14 spent a lot of time explaining them to, because they
15 had an acute interest because of plants in their
16 states. One of those persons is currently the
17 President of the United States, and the other one is
18 the Secretary of State. That's one of the things that
19 they know about nuclear power plants, is that EPA and
20 NRC do things differently, and they're probably both a
21 little suspect as to whether either agency knows what
22 they're doing in that regard.

23 MEMBER BANERJEE: Could I ask a question?

24 MR. ANDERSON: Sure.

25 MEMBER BANERJEE: I mean, there is a model

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 to convert the concentration, I presume, to a dose of
2 some sort.

3 MR. ANDERSON: Yes.

4 MEMBER BANERJEE: Within this model, there
5 are presumptions which have to be made. One of these
6 presumably has to do with intake of how much stuff
7 you're taking in, and the other is how you convert
8 that into a dose.

9 MR. ANDERSON: Right.

10 MEMBER BANERJEE: Where is the major
11 problem, in the intake model, or in the conversion
12 from what you take in into what dose you get?

13 MR. ANDERSON: Well, it's -- you mean
14 between the two agencies?

15 MEMBER BANERJEE: Yes.

16 MR. ANDERSON: Yes. Okay. Intake is one.
17 A second one is the period of time over which
18 lifetime dose is assessed. EPA uses 30 years, we use
19 50, is my recollection. I could be wrong in that now,
20 but that was the case at least several years ago when
21 we were dealing with this. And another one is that
22 what EPA drives for is risk, a risk number. They're
23 looking for risk in the range of fatal cancer, 10 to
24 the minus 4, 10 to the minus 6, so they go beyond dose
25 to risk. And it's that final conversion and take me

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 at face value here, having used the 50-year old
2 methodology to calculate the dose, they actually use
3 the most contemporary conversion of dose-to-risk that
4 exists. In fact, it's so contemporary, a lot of us
5 aren't even sure it's real because it's one step
6 beyond sort of generally accepted global practice.

7 MEMBER RYAN: Ralph, one other point I
8 would add. If you have an intake, and you know the
9 intake, you could think about what is the calculated
10 dose. If you're within an order of magnitude for a
11 given single intake, that's not a bad way to think
12 about your precision or accuracy for an intake.
13 Tritium and a couple of radionuclides are a little bit
14 more accurate than that, but for solid -

15 MEMBER BANERJEE: You've lost me. What
16 you're saying is if you take a certain amount in,
17 there's a certain uncertainty in the dose that you
18 calculate?

19 MEMBER RYAN: Yes.

20 MEMBER BANERJEE: By whatever model you
21 use.

22 MEMBER RYAN: Fifty percent or better.

23 MEMBER BANERJEE: Right. Okay.

24 MR. ANDERSON: I'll also say that if a
25 worker came to the U.S., got an intake, we calculated

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 a dose, assigned that dose in their record and sent
2 them back to France, for example, my French colleagues
3 would recalculate their dose because it would be a
4 different number. Not just because of what we talked
5 about, but also because of the basic differences in
6 the vintage of how radioactivity itself translates to
7 the dose. I don't think that's a good place to be.

8 I'll mention to you, also, that all the
9 vendors of the nuclear power plants have two sets of
10 analyses, they have one for the United States, and
11 they have one for all the other countries they might
12 want to sell reactors in. Within figuring out the
13 design, Tim Frye had mentioned this, the ultimate
14 criteria that you use for accident dose are not the
15 Part 100 criteria that you're probably intimately
16 familiar with; that is, the 25 rem whole-body, and the
17 300 rem to the thyroid. It's actually the 25 rem
18 total effective dose equivalent that was promulgated
19 some years back in Part 52, so you uniquely you do
20 that calculation, but then when you do control room
21 habitability, then you end up either using ICRP 26.
22 Arguably, you could use ICRP 2, probably not, and then
23 more likely you appeal to the -- not appeal, you
24 propose to the NRC that you're going to use more
25 contemporary dose conversion criteria. So even

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 internally in analyzing the radiological aspects of a
2 new design, you're using different methods to look at
3 different things.

4 This gentleman up here has to live this
5 every day in reviewing license applications, and
6 design documents. And, in fact, recently when we
7 worked our way through the whole issue of off-site
8 dose calculation and so forth, we're really having to
9 come to grips with that. Fortunately, we found some
10 solutions to that, but it was getting very confusing
11 when we were trying to translate applications
12 calculated population doses to what that means in
13 terms of effluents discharged, and so forth. So all
14 of this just tells us that we ought to get it
15 eventually updated, and set the stage for yet the next
16 generation of reactors that's going to come along.

17 MEMBER MAYNARD: You stated something that
18 piqued my interest. You said that they would
19 recalculate the dose when they went back overseas.
20 What about when we bring overseas workers into here,
21 do we accept their exposure numbers, or do we
22 recalculate based on our methodology?

23 MR. ANDERSON: In the instances where it's
24 been limiting, we do recalculate. This is infrequent.
25 I shouldn't characterize -- nuclear power plants, in

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 general, you don't have significant intakes. But
2 occasionally you do have one where it's in the record,
3 and then you take a look at it, try to ascertain how
4 it was calculated, and see how that would translate in
5 your own space, because when you make your exposure
6 reports, those are the kinds of things that you need
7 to take into account.

8 MEMBER RYAN: Just to clarify for Otto's
9 benefit, that's really a question of internal
10 radiation exposure, rather than a badge reading.

11 MR. ANDERSON: Yes.

12 MEMBER RYAN: The badges will translate
13 fairly clearly external dose, but we're talking about
14 an internal intake where there would be a
15 recalculation.

16 MEMBER BANERJEE: You said something more
17 - one last question.

18 MR. ANDERSON: Sure.

19 MEMBER BANERJEE: The utilities, the
20 vendors, or whatever maintain two sets of books,
21 essentially.

22 MR. ANDERSON: Yes.

23 MEMBER BANERJEE: One for everybody else,
24 and one for the United States. Does that mean that
25 everybody else is consistent with each other, and we

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 are the only ones -

2 MR. ANDERSON: Well, I misspoke myself.
3 Japan is like us, so it's not all countries and us
4 only. But in general, the plants that are build --
5 the countries that are currently moving forward with
6 new nuclear power plants use the ICRP 60-based
7 methodology; whereas, our analysis, in general, is
8 either ICRP 26 or ICRP 2-based, depending on what the
9 specific aspect is.

10 MEMBER BANERJEE: And who else is
11 maintaining a set of books like us?

12 MR. ANDERSON: There is yet another
13 problem, and I hate to throw kerosene on the fire. We
14 also have the problem of international units
15 independent of all of this, so they've got a set of
16 books that talk about becherels and sieverts, and our
17 set of books is talking about curies and rem. Now,
18 rem and sievert isn't quite so hard because you can
19 divide by 100 and get there in your head. Becherels
20 and sieverts is a little more complicated, and is more
21 suggestive of the type of thing that caused us to
22 crash a lander on a planet when we didn't do the
23 metric conversion right. So that's why they maintain
24 two completely independent sets of books.

25 MEMBER BANERJEE: Is it just Japan and us

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 who are in this group, or are there other people?

2 DR. POWERS: It's more complicated than
3 that, because in some cases when a country buys a
4 plant, they buy the regulations from the vendor. For
5 instance, Spain, or U.S. plants uses U.S. regulations,
6 where the plants they use vending country regulations,
7 so it's not as clear as that.

8 MEMBER BANERJEE: So let's talk about
9 China and India for who are planning to buy 12 plants,
10 AP 1000. Are they going to adopt the American
11 regulations for AP 1000, or are they going to take the
12 French? I mean, what's going to happen?

13 MR. ANDERSON: I don't think there's an
14 answer to -

15 DR. POWERS: Why do you care?

16 MEMBER BANERJEE: Because there are lots
17 of plants being built there.

18 DR. POWERS: Yes, but you don't regulate
19 them.

20 MEMBER BANERJEE: No, but I'm just
21 interested in understanding what is the -- are they
22 going to -

23 MR. ANDERSON: My best understanding is
24 that there are still a lot of decisions to be made in
25 that regard; that is, it isn't set. The most recent

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 interaction I had with Indian colleagues a few years
2 ago, they were still using ICRP 26.

3 MEMBER RYAN: We have just a few minutes -

4
5 MR. ANDERSON: I'm 10 years out of date on
6 that.

7 MEMBER RYAN: Are there any other
8 questions for the Staff?

9 MEMBER BLEY: Yes, I've got one. I mean,
10 it sounds like a very significant job to reconcile the
11 U.S. regulations for NRC. Are there really
12 significant activities interagency internationally,
13 and do they have any hope of trying to get that part
14 of it under control?

15 DR. BUTLER: Interagency, other agencies
16 are considering updating their standards, as well.

17 MEMBER BLEY: Independently, or are you
18 working in some kind of -

19 DR. BUTLER: Well, there's the ISCWR's
20 that interagency Steering Committee, where they keep
21 each other apprized. We keep each other apprized of
22 what we're considering. For example, DOE recently
23 moved to ICRP 60, and they're in their 3-year
24 implementation period as we speak for ICRP 60. Now,
25 will they consider moving forward to 103? We'll have

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 to keep that conversation open.

2 MEMBER RYAN: I think it's fair to say
3 that the ISCWR's working group at least keeps every
4 agency apprized of the other agency's activities, but
5 it's probably also fair to say that there's not really
6 close alignment with all their decision making as time
7 marches on. So awareness is there, but not
8 necessarily concurrence.

9 MR. ANDERSON: Now, I'll mention that
10 we've started reaching out independently, at least in
11 interacting with the Environmental Protection Agency.

12 What should be of great interest is that under law,
13 under the Reorganization Act of 1974, the EPA actually
14 sets the generally applicable environmental radiation
15 standards from which all of the NRC effluent
16 environmental standards are derived; that is, they're
17 required to assure implementation of these EPA
18 standards. The EPA standards are ICRP 2-based. That
19 hasn't created any significant issues over the years
20 with radiological effluents from nuclear power plants.

21 I suggest to you that people are looking very hard
22 now at how it might affect future technologies or
23 closing a fuel cycle. The antiquated criteria that
24 are in there may challenge us when NRC goes to
25 implement regulations to license reprocessing and the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 like in the future. That's probably a very fruitful
2 area at some point down the road to hear about from
3 those folks.

4 MEMBER RYAN: I think in our remaining
5 nine minutes, we have another comment. Would you tell
6 us who you are, sir?

7 MR. BLAND: Stewart Bland with Chesapeake
8 Nuclear Services. I wanted to pick up just quickly on
9 the issue of the international and the global
10 community. Back in October, I had the privilege of
11 being on an NRC-sponsored two-week training program
12 for the Chinese regulators in the AP 1000. And the
13 main purpose was to support the Chinese in their
14 adopting a lot of NRC's evaluations that have been
15 done to certify the AP 1000.

16 In that process, I was doing the training
17 on the Chapter 11 and Chapter 12 parts of the FSAR.
18 Some of the more in-depth discussions and longer
19 discussions were actually held related to the
20 difference in the radiation standards that we have,
21 and what we evaluated under for the Part 20, for the
22 Appendix I versus the radiation standards that they
23 have, which are more based upon the 2 rem, and the
24 more up-to-date ICRP. And, whereas, they're trying to
25 look at the evaluations that we've done, which are now

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 based upon old dosimetry, old Part 20, and adopt that
2 so they do not have to go through a lot of other
3 detailed reviews and evaluations, and they're hitting
4 a roadblock there. So that was rather problematic for
5 them in their evaluations, and we did spend a lot of
6 time discussing what were the differences and the
7 basis for those.

8 MEMBER RYAN: Thank you. Any other
9 questions for the Staff from members?

10 DR. BUTLER: I wanted to make one other
11 comment.

12 MEMBER RYAN: Yes, and any final comments?
13 Yes, please.

14 DR. BUTLER: Yes. I just wanted to say
15 that we are really looking forward to working with the
16 ACRS during our technical basis development, if the
17 Commission decides to take the Staff's recommended
18 option. We don't know as of yet whether the
19 Commission will vote for the recommendations of the
20 Staff, but if they do, we look forward to continued
21 dialogue with you.

22 MEMBER RYAN: Let me thank you, Dr.
23 Butler, and Jean-Claude, both for your presentations
24 and participation. I think it's been a full and
25 broad-reaching discussion. We've had some good input

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 from stakeholders already in our meeting today, and I
2 think you've given us what we need to formulate our
3 thoughts for a letter. So with that, I'll turn it back
4 to you, Mr. Chairman.

5 CHAIR BONACA: Thank you, and I second the
6 comments of Dr. Ryan, for the excellent presentation.

7 And at this point, we're going to take a break until
8 10:15, and we will start at that point with Beaver
9 Valley. Are we going to be off the record after -

10 MEMBER SHACK: I think so. We're going to
11 be off the record for the rest of the day.

12 CHAIR BONACA: Okay. So 10:15.

13 (Whereupon, the proceedings went off the
14 record at 9:53:59 a.m.)

15
16
17
18
19
20
21
22
23
24
25

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701



U.S.NRC
UNITED STATES NUCLEAR REGULATORY COMMISSION

Protecting People and the Environment

Options to Revise Radiation Protection Regulations

SECY-08-0197

*Advisory Committee on Reactor Safeguards
February 6, 2009*

Kimyata Morgan Butler, Ph.D.

Office of Federal and State Materials and Environmental Management Programs

Background

- **NRC Staff Information briefing to ACRS on November 6, 2008**
 - Presentation of background information on ICRP recommendations, radiation protection
 - Discussion of staff identified technical issues in 10 CFR Part 20 and 10 CFR Part 50
- **SECY-08-0197, December 18, 2008, is publically available.**

SECY-08-0197

- **Policy Issue Notation Vote paper provided to Commission on December 18, 2008**
- **Provides Options for next steps regarding NRC radiation protection standards**
- **Provides Background on technical issues in 10 CFR Part 20 and 10 CFR Part 50**
- **Recommends Commission approval for staff to undertake stakeholder dialogue and technical basis development**

Regulatory Options

- **Options include:**
 - **No Action**
 - **Update 10 CFR Part 50 and Part 50 Appendix I**
 - **Engage Stakeholders & Develop Technical Basis to Increase Alignment of NRC Radiation Protection Framework with ICRP 103**
- **Factors considered**
 - **Schedule for technical information**
 - **New reactor licensing**
 - **Other issues that may be raised outside ICRP changes**
 - **Resources**

Option 1: No Action

- **Commission concludes there is no need for changes in any of the current regulations**
- **Pros**
 - No resources needed
- **Cons**
 - Not responsive to current scientific information
 - Regulations remain inconsistent
 - Does not improve international consistency
 - Nuclear Power industry has stated preference to update requirements

Option 2: Update Part 50

- **Commission concludes there is no basis to update Part 20, but agrees to update Part 50 and Part 50 Appendix I to current Part 20 methodology**
- **Pros**
 - **Reduced burden for nuclear power by improving consistency between Part 20 and Part 50**
- **Cons**
 - **Not responsive to current scientific information**
 - **Does not improve international consistency**
 - **Only partially responsive to industry interest**

Option 3: Engage Stakeholders & Develop Technical Basis

- **Commission concludes there is sufficient basis to continue dialogue and develop technical basis**
- **Pros**
 - **Starts process that could improve scientific basis, improve internal regulatory consistency, and increase international consistency**
 - **Engages stakeholders early to identify issues, and solutions, before beginning rulemaking**
- **Cons**
 - **Resources necessary for stakeholder engagement and technical basis development**

Staff Recommendation

- **Option 3, begin process of moving towards greater degree of alignment**
- **Begin stakeholder dialogue with stakeholder communities on technical issues and options**
- **Begin technical basis development Interact with other Federal and State Agencies to foster consistency in directions and approach**
- **Provide recommendations for rulemaking when technical basis available**

Questions? Questions?



Background Materials

Background

- **Most recent rulemaking to incorporate the recommendations of the ICRP into 10 CFR 20 was completed in 1991, and was based primarily on ICRP Publications 26 (1977)**
- **Regulations that contained explicit dose criteria, rather than cross-references to Part 20, were not updated in 1991, and remain based primarily on ICRP Publications 1 (1958) and 2 (1959)**

Background (continued)

- **NRC staff recommended in 2001 that the Commission wait for next set of ICRP recommendations, and begin Technical Basis development**
- **Commission agreed in April 2002, but did not approve Technical Basis efforts**
- **ICRP Recommendations published in December 2007, as Publication 103, following considerable public consultation**

Considerations

- **Numerous inquiries to Commission and Staff about the status of updates to U.S. radiation protection regulations**
- **Globalization of economy and industry places greater importance on regulatory consistency**
- **Other countries and international organizations already starting process of update**
- **Interest from nuclear power industry to update standards and increase consistency**

Initial Interactions

- Staff has engaged States, nuclear industry, medical community, ACRS, ACMUI
- General agreement that updates and modifications are warranted
- Impacts of technical issues are highly dependent upon approach taken for resolution
- Lack of information for some licensee segments, particularly industrial and medical
- States will use revision as basis to regulate both AEA and non-AEA radiation activities

Technical Issues for Part 20

- **Total Effective Dose**
- **Constraints**
 - **Occupational Exposure**
 - **Public Exposure**
- **Dose limits**
 - **Occupational**
 - **Public**
 - **Embryo/fetus of Declared Pregnant Woman**
- **Numerical values of weighting factors and Appendix B**

Technical Issues Part 50, App I


- **Align App. I criteria concepts with Part 20**
- **Reconsider criteria in Sect. II.A, II.B, and II.C**
- **Update definition of dose receptors in Sect. II and IV**
- **Update cost-benefit criteria in Sect. II.D**
- **Assess whether Sect. I and V need qualifiers, i.e., existing fleet of reactors vs. new plants**

Technical Issues Part 50, App I

- **Revise Sect. I in differentiating applicability between LWR, Non-LWR, and NGNP**
- **Redefine compliance requirements for “licensed operation” for sites with multiple licensees**
- **Assess whether compliance with 40 CFR Part 190 needs further elaboration in Part 20 or guidance**


ICRP Publication 103

- Consolidated material from ICRP Publication 60 and subsequent publications
- Maintained fundamental principles of: Justification, Optimization, and Limitation
- Radiation risk remains as $\sim 5 \times 10^{-4}$ per rem
- LNT for prospective radiation control programs



ICRP Publication 103

- Moved to a “situation” based framework
 - Planned Exposure Situations
 - Emergency Exposure Situations
 - Existing Exposure Situations
- Emphasized Optimization using Dose Constraints
- Retained Dose Limits and values
 - Occupational Exposure: 10 rem / 5 years, max of 5 rem in any one year
 - Public Exposure: 100 mrem
 - Embryo/Fetus: 100 mrem




ICRP Continuing Work

- Assessment of new scientific information has resulted in new tissue and radiation weighting factors
- Efforts now underway to calculate new dose conversion factors using updated models and information
- Commonly used radionuclides to be available in 2011 ... Complete set 2014



International Standards Work

- **IAEA continuing revision of Basic Safety Standards.**
 - Draft reviewed by RASSC in November
 - Additional drafting in topical meetings
 - Further review at RASSC in June, 2009
 - Eventual Member State comment
- **Draft moves to adopt ICRP Recommendations**



International Standards Work

- **Revision of Euratom Basic Safety Standards**
 - Revision of BSS Directive 96/29
 - Incorporate new ICRP recommendations
 - Consolidate all existing legislation
 - Integration of natural and artificial sources
 - Protection of the Environment
- **Draft to Article 31 Group of Experts Plenary
October, 2009**

